EFFECTOR Therapeutics Net Income vs. Book Value Per Share

EFTRWDelisted Stock  USD 0  0.00  0.00%   
Based on EFFECTOR Therapeutics' profitability indicators, EFFECTOR Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in December. Profitability indicators assess EFFECTOR Therapeutics' ability to earn profits and add value for shareholders.
For EFFECTOR Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of EFFECTOR Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well EFFECTOR Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between EFFECTOR Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of EFFECTOR Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Please note, there is a significant difference between EFFECTOR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if EFFECTOR Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, EFFECTOR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

EFFECTOR Therapeutics Book Value Per Share vs. Net Income Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining EFFECTOR Therapeutics's current stock value. Our valuation model uses many indicators to compare EFFECTOR Therapeutics value to that of its competitors to determine the firm's financial worth.
EFFECTOR Therapeutics is rated # 3 in net income category among its peers. It also is rated # 3 in book value per share category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the EFFECTOR Therapeutics' earnings, one of the primary drivers of an investment's value.

EFFECTOR Book Value Per Share vs. Net Income

Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

EFFECTOR Therapeutics

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(35.81 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

EFFECTOR Therapeutics

Book Value per Share

 = 

Common Equity

Average Shares

 = 
0.21 X
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.

EFFECTOR Book Value Per Share Comparison

EFFECTOR Therapeutics is currently under evaluation in book value per share category among its peers.

EFFECTOR Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on EFFECTOR Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of EFFECTOR Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the EFFECTOR Therapeutics' important profitability drivers and their relationship over time.

Use EFFECTOR Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if EFFECTOR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EFFECTOR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

EFFECTOR Therapeutics Pair Trading

EFFECTOR Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to EFFECTOR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace EFFECTOR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back EFFECTOR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling EFFECTOR Therapeutics to buy it.
The correlation of EFFECTOR Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as EFFECTOR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if EFFECTOR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for EFFECTOR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your EFFECTOR Therapeutics position

In addition to having EFFECTOR Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Driverless Cars Thematic Idea Now

Driverless Cars
Driverless Cars Theme
It encompasses large technology companies, automotive makers, security firms, and thematic ETFs across multiple industries. These entities are directly or indirectly involved in shaping the development and marketing of self-driving vehicles. The Driverless Cars theme has 36 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Driverless Cars Theme or any other thematic opportunities.
View All  Next Launch
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in EFFECTOR Pink Sheet

If you are still planning to invest in EFFECTOR Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EFFECTOR Therapeutics' history and understand the potential risks before investing.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing